A Repeat-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of GSK1278863 and Metabolites in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

Next Previous
Trial Profile

A Repeat-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of GSK1278863 and Metabolites in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Daprodustat (Primary)
  • Indications Anaemia
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 13 Oct 2017 Status changed from recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 05 Jun 2017 Planned End Date changed from 1 Jun 2017 to 16 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top